Skip to main content

Alerts and Recalls

  • Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles

    Tuesday, January 14, 2020
    Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expiration date June 2021) in 100 count bottles, NDC 51672-4131-1 to the consumer level. This single lot of Lamotrigine 100 mg...

    Read More
  • Elevated Influenza Activity: Influenza B/Victoria and A(H1N1)pdm09 Viruses are the Predominant Viruses

    Monday, January 13, 2020

    This health advisory notifies clinicians that influenza activity remains high in the United States. Ongoing elevated activity is due to influenza B/Victoria viruses, increasing circulation of influenza A(H1N1)pdm09 viruses, and low levels of influenza B/Yamagata and influenza A(H3N2) viruses. CDC’s influenza forecasts suggest that national influenza activity will remain elevated for several more weeks. Because influenza activity is elevated and both influenza A and B virus infections can cause severe disease and death, this health advisory also serves as a reminder that early treatment with antiviral medications improves outcomes in patients with influenza. Early treatment with antiviral medications is recommended for hospitalized patients and high-risk outpatients, including children younger than two years. Clinicians should continue efforts to vaccinate patients for as long as influenza viruses are circulating, and promptly start antiviral treatment of severely ill and high-risk patients with suspected influenza without waiting for laboratory confirmation.

    Read More
  • Glenmark Pharmaceuticals Inc., USA Voluntarily Recalls All Unexpired Lots of its Ranitidine Tablets and Ceases Distribution

    Thursday, December 19, 2019
    Glenmark Pharmaceutical Inc., USA (“Glenmark”) today announced the voluntary recall of all unexpired lots of Ranitidine Tablets, 150 mg and 300 mg, to the consumer level. The recalled lots of Ranitidine Tablets 150 mg and 300 mg, which are listed in Attachment B, are being recalled...

    Read More
  • Medtronic Recalls SynchroMed II Implantable Drug Infusion Pump

    Tuesday, December 17, 2019
    Medtronic received reports of early permanent motor stall due to the potential presence of foreign particles inside the pump motor assembly. Permanent motor stall could prevent the infusion of drugs to the patient, which could cause serious injury, such as drug withdrawal, the return of symptoms of...

    Read More
  • B. Braun Medical Inc. Issues Voluntary Nationwide Recall of Twenty-Two Lots of Blood Administration Sets

    Monday, December 2, 2019
    B. Braun Medical Inc. [B. Braun] initiated a voluntary recall of twenty-two (22) lots of Blood Administration Sets. The recalled blood administration sets are used to administer blood from a container to a patient's vascular system through an IV catheter inserted into a vein or central venous...

    Read More
  • The FDA has announced a recall of 13 Fr. Trialysis Catheter with Alphacurve

    Monday, November 25, 2019
    The FDA has announced a recall of 13 Fr. Trialysis Catheter with Alphacurve. Catalog No. 5653150 UDI 00801741066023 Power-Trialysis Short-Term Alphacurve Dialysis Catheter with a third internal lumen for IV therapy, power injection of contrast media, and central venous pressure monitoring, because...

    Read More
  • Precision Dose Inc. Issues Voluntary Nationwide Recall of Ranitidine Oral Solution

    Friday, November 22, 2019
    Precision Dose Inc. is voluntarily recalling 5 lots of Ranitidine Oral Solution, USP 150 mg/10 mL to the consumer level. Ranitidine Oral Solution, USP 150 mg/10 mL, is being recalled because of potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA. This recall is being...

    Read More
  • Amneal Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Ranitidine

    Wednesday, November 13, 2019
    Amneal Pharmaceuticals, LLC. Bridgewater, New Jersey is voluntarily recalling Ranitidine Tablets, 150 mg and 300 mg, and Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL to the consumer level. A listing of the recalled lots is identified below.

    Read More
  • American Health Packaging Issues Voluntary Nationwide Recall of Ranitidine Syrup

    Tuesday, November 12, 2019
    American Health Packaging is voluntarily recalling eight lots of Ranitidine Syrup (Ranitidine Oral Solution USP) 150 mg/10 mL Liquid Unit Dose Cups to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the...

    Read More
  • Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 38 Lots of Ranitidine

    Friday, November 8, 2019
    Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 1 lot of Ranitidine Tablets 150mg to the retail level and 37 lots of Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL to the consumer level due to the detection of NDMA (Nitrosodimethylamine) Impurity in...

    Read More